Baselt R C, Hanson V W
Res Commun Chem Pathol Pharmacol. 1982 Oct;38(1):113-24.
The oral efficacy of several chelating drugs, disulfiram, sodium diethyldithiocarbamate (dithiocarb), and D-penicillamine, was studied in relation to their ability to prevent lethality due to acute inhalation exposure to nickel carbonyl. Dithiocarb and, to a lesser degree, D-penicillamine were found to be especially effective as therapeutic agents. Since dithiocarb is chemically unstable (although it is an active metabolite of disulfiram), its practical usefulness outside the laboratory is limited. Therefore, further investigation was conducted to elucidate the pharmacokinetic differences between dithiocarb and disulfiram in order to explain their relative efficacies. Kinetic analysis indicated that oral dithiocarb provided moderately high but prolonged plasma levels of active chelating agent, while disulfiram resulted in a very high but transient level. These results suggested that small, repeated oral doses of disulfiram would be just as effective in nickel carbonyl poisoning as a single large dithiocarb dose. This was not borne out in subsequent experiments. Investigation into the tissue distribution of inhaled 63Ni-labeled nickel carbonyl 24 hours after exposure showed that all three chelating agents significantly reduced the amounts of nickel in heart and lung, and D-penicillamine further reduced the amounts in blood and kidney. Only disulfiram increased on average the nickel retained in brain tissue, possibly accounting for its limited efficacy. Our results suggest caution in the use of oral disulfiram in human nickel carbonyl intoxication.
研究了几种螯合药物双硫仑、二乙氨基二硫代甲酸钠(二硫代甲酸盐)和D-青霉胺的口服疗效与其预防急性吸入羰基镍所致致死性的能力之间的关系。发现二硫代甲酸盐以及程度稍轻的D-青霉胺作为治疗药物特别有效。由于二硫代甲酸盐化学性质不稳定(尽管它是双硫仑的活性代谢产物),其在实验室之外的实际用途有限。因此,进行了进一步研究以阐明二硫代甲酸盐和双硫仑之间的药代动力学差异,以便解释它们的相对疗效。动力学分析表明,口服二硫代甲酸盐可使活性螯合剂的血浆水平适度升高但持续时间较长,而双硫仑则导致血浆水平非常高但短暂。这些结果表明,小剂量重复口服双硫仑在羰基镍中毒方面与单次大剂量二硫代甲酸盐一样有效。但后续实验并未证实这一点。对暴露24小时后吸入的63Ni标记的羰基镍的组织分布进行的研究表明,所有三种螯合药物均显著降低了心脏和肺部的镍含量,D-青霉胺进一步降低了血液和肾脏中的镍含量。只有双硫仑平均增加了脑组织中保留的镍含量,这可能是其疗效有限的原因。我们的结果表明,在人体羰基镍中毒中使用口服双硫仑时应谨慎。